BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 27729324)

  • 21. [Status of Langerhans cell histiocytosis in children and adults].
    Kudo K
    Rinsho Ketsueki; 2019; 60(9):1308-1316. PubMed ID: 31597857
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association between clinicopathologic characteristics and BRAF
    Huang H; Lu T; Sun Y; Li S; Li J; Xu K; Feng RE; Xu ZJ
    Thorac Cancer; 2019 Oct; 10(10):1984-1992. PubMed ID: 31441596
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Frequent KIT mutations in skin lesions of patients with BRAF wild-type Langerhans cell histiocytosis.
    Tóth B; Kiss N; Hársing J; Kárpáti S; Csomor J; Bödör C; Tímár J; Rásó E
    Virchows Arch; 2020 Nov; 477(5):749-753. PubMed ID: 32372223
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Somatic ARAF mutations in pediatric Langerhans cell histiocytosis: clinicopathologic, genetic and functional profiling.
    Liu R; Guo Y; Han L; Feng S; Cao J; Sun Y; Cao Z; Cui X
    Clin Exp Med; 2023 Dec; 23(8):5269-5279. PubMed ID: 37572153
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High Prevalence of
    Liu X; Zhang Y; Zhou CX
    Int J Surg Pathol; 2019 Dec; 27(8):836-843. PubMed ID: 31203679
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MAP2K1 and MAP3K1 mutations in Langerhans cell histiocytosis.
    Nelson DS; van Halteren A; Quispel WT; van den Bos C; Bovée JV; Patel B; Badalian-Very G; van Hummelen P; Ducar M; Lin L; MacConaill LE; Egeler RM; Rollins BJ
    Genes Chromosomes Cancer; 2015 Jun; 54(6):361-8. PubMed ID: 25899310
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pediatric Langerhans cell histiocytosis: the impact of mutational profile on clinical progression and late sequelae.
    Nann D; Schneckenburger P; Steinhilber J; Metzler G; Beschorner R; Schwarze CP; Lang P; Handgretinger R; Fend F; Ebinger M; Bonzheim I
    Ann Hematol; 2019 Jul; 98(7):1617-1626. PubMed ID: 30923995
    [TBL] [Abstract][Full Text] [Related]  

  • 28. BRAF Mutation Correlates With High-Risk Langerhans Cell Histiocytosis and Increased Resistance to First-Line Therapy.
    Héritier S; Emile JF; Barkaoui MA; Thomas C; Fraitag S; Boudjemaa S; Renaud F; Moreau A; Peuchmaur M; Chassagne-Clément C; Dijoud F; Rigau V; Moshous D; Lambilliotte A; Mazingue F; Kebaili K; Miron J; Jeziorski E; Plat G; Aladjidi N; Ferster A; Pacquement H; Galambrun C; Brugières L; Leverger G; Mansuy L; Paillard C; Deville A; Armari-Alla C; Lutun A; Gillibert-Yvert M; Stephan JL; Cohen-Aubart F; Haroche J; Pellier I; Millot F; Lescoeur B; Gandemer V; Bodemer C; Lacave R; Hélias-Rodzewicz Z; Taly V; Geissmann F; Donadieu J
    J Clin Oncol; 2016 Sep; 34(25):3023-30. PubMed ID: 27382093
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of Langerhans cell histiocytosis: role of BRAF/MAPK inhibition.
    Abla O; Weitzman S
    Hematology Am Soc Hematol Educ Program; 2015; 2015():565-70. PubMed ID: 26637773
    [TBL] [Abstract][Full Text] [Related]  

  • 30. BRAF V600E mutation in childhood Langerhans cell histiocytosis correlates with multisystem disease and poor survival.
    Bhatia P; Singh M; Sharma M; Sharma A; Kakkar N; Radhika S; Trehan A; Bansal D
    Blood Cells Mol Dis; 2020 May; 82():102356. PubMed ID: 32171112
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Progress towards molecular-based management of childhood Langerhans cell histiocytosis.
    Héritier S; Emile JF; Hélias-Rodzewicz Z; Donadieu J
    Arch Pediatr; 2019 Jul; 26(5):301-307. PubMed ID: 31281037
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Activating BRAF V600E mutation in aggressive pediatric Langerhans cell histiocytosis: demonstration by allele-specific PCR/direct sequencing and immunohistochemistry.
    Méhes G; Irsai G; Bedekovics J; Beke L; Fazakas F; Rózsa T; Kiss C
    Am J Surg Pathol; 2014 Dec; 38(12):1644-8. PubMed ID: 25118810
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical and prognostic characteristics of 95 cases of Langerhans cell histiocytosis in children: a single-institute experience from 2013 to 2020.
    Tang X; Gao J; Ma ZG; Guo X; Li Q; Wan Z; Sun JJ
    Ann Med; 2021 Dec; 53(1):1537-1546. PubMed ID: 34459688
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [BRAF-V600E mutation and its clinical significance in children with Langerhans cell histiocytosis].
    Tang X; Guo X; Sun LY; Ai Y; Yang X; Sun JJ; Wu JR; Gao J
    Zhongguo Dang Dai Er Ke Za Zhi; 2018 Apr; 20(4):290-294. PubMed ID: 29658453
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recurrent BRAF mutations in Langerhans cell histiocytosis.
    Badalian-Very G; Vergilio JA; Degar BA; MacConaill LE; Brandner B; Calicchio ML; Kuo FC; Ligon AH; Stevenson KE; Kehoe SM; Garraway LA; Hahn WC; Meyerson M; Fleming MD; Rollins BJ
    Blood; 2010 Sep; 116(11):1919-23. PubMed ID: 20519626
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Custom pyrosequencing assay to detect short
    Jouenne F; Sadoux A; Lorillon G; Louveau B; Bugnet E; Meignin V; Mourah S; Tazi A
    J Clin Pathol; 2021 Aug; 74(8):533-536. PubMed ID: 32873703
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevalence of the
    Stathi D; Yavropoulou MP; Allen CE; Abhyankar H; Scull B; Tsoli M; Andreakos E; Kaltsas G; Makras P
    Pediatr Hematol Oncol; 2022 Sep; 39(6):540-548. PubMed ID: 35139731
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of the V600D mutation in Exon 15 of the BRAF oncogene in congenital, benign langerhans cell histiocytosis.
    Kansal R; Quintanilla-Martinez L; Datta V; Lopategui J; Garshfield G; Nathwani BN
    Genes Chromosomes Cancer; 2013 Jan; 52(1):99-106. PubMed ID: 22996177
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The use of BRAF V600E mutation-specific immunohistochemistry in pediatric Langerhans cell histiocytosis.
    Ballester LY; Cantu MD; Lim KPH; Sarabia SF; Ferguson LS; Renee Webb C; Allen CE; McClain KL; Mohila CA; Punia JN; Roy A; López-Terrada DH; John Hicks M; Fisher KE
    Hematol Oncol; 2018 Feb; 36(1):307-315. PubMed ID: 28219109
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CNS Langerhans cell histiocytosis: Common hematopoietic origin for LCH-associated neurodegeneration and mass lesions.
    McClain KL; Picarsic J; Chakraborty R; Zinn D; Lin H; Abhyankar H; Scull B; Shih A; Lim KPH; Eckstein O; Lubega J; Peters TL; Olea W; Burke T; Ahmed N; Hicks MJ; Tran B; Jones J; Dauser R; Jeng M; Baiocchi R; Schiff D; Goldman S; Heym KM; Wilson H; Carcamo B; Kumar A; Rodriguez-Galindo C; Whipple NS; Campbell P; Murdoch G; Kofler J; Heales S; Malone M; Woltjer R; Quinn JF; Orchard P; Kruer MC; Jaffe R; Manz MG; Lira SA; Parsons DW; Merad M; Man TK; Allen CE
    Cancer; 2018 Jun; 124(12):2607-2620. PubMed ID: 29624648
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.